Description
Thomas J. Fuchs, Dr.sc., joined Eli Lilly and Company as its first chief AI officer in October 2024. In this role, Fuchs provides vision, strategic direction and overall leadership of AI initiatives across Lilly, including drug discovery, clinical trials, manufacturing, commercial activities and internal functions. He also identifies, builds and manages AI and machine learning solutions to help Lilly provide medicines to patients around the world.
Before joining Lilly, Fuchs was the dean and inaugural department chair for AI and Human Health at Mount Sinai, director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and the endowed Barbara T. Murphy professor for AI and computational pathology at the Icahn School of Medicine at Mount Sinai. Prior, Fuchs held positions at Memorial Sloan Kettering Cancer Center, NASA's Jet Propulsion Laboratory and the California Institute of Technology, and founded three companies, including Paige AI. Fuchs holds a doctoral degree in machine learning from ETH Zurich and a master’s degree in technical mathematics from Graz Technical University in Austria.
